GlycoDesign expands phase II clinical trials for GD0039.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009656:North America
D000970:Antineoplastic Agents